Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2002 1
2006 1
2007 1
2008 1
2010 4
2011 1
2012 5
2013 8
2014 17
2015 13
2016 16
2017 19
2018 33
2019 24
2020 53
2021 62
2022 56
2023 51
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Results by year

Filters applied: . Clear all
Page 1
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Wu W, et al. Pharmacol Res. 2021 Sep;171:105780. doi: 10.1016/j.phrs.2021.105780. Epub 2021 Jul 21. Pharmacol Res. 2021. PMID: 34302977 Free PMC article.
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant, primary brain tumor with a 5-year survival of 7.2%. ...The standard treatment for GBMs is surgical resection followed by chemoradiotherapy. The robust DNA repair and self-renewing capabil …
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant, primary brain tumor with a 5-year survival of 7 …
Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.
Sareen H, Ma Y, Becker TM, Roberts TL, de Souza P, Powter B. Sareen H, et al. Int J Mol Sci. 2022 Aug 9;23(16):8835. doi: 10.3390/ijms23168835. Int J Mol Sci. 2022. PMID: 36012105 Free PMC article. Review.
Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that needs better treatment modalities. ...
Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that needs better treatment modalities. ...
Wogonin and its analogs for the prevention and treatment of cancer: A systematic review.
Banik K, Khatoon E, Harsha C, Rana V, Parama D, Thakur KK, Bishayee A, Kunnumakkara AB. Banik K, et al. Phytother Res. 2022 May;36(5):1854-1883. doi: 10.1002/ptr.7386. Epub 2022 Jan 31. Phytother Res. 2022. PMID: 35102626 Review.
Numerous in vitro and in vivo studies have revealed that WOG exerts immense therapeutic potential against bladder cancer, breast cancer, cholangiocarcinoma, cervical cancer, colorectal cancer, gallbladder cancer, gastric cancer, glioblastoma, head and neck cancer, hepatic …
Numerous in vitro and in vivo studies have revealed that WOG exerts immense therapeutic potential against bladder cancer, breast cancer, cho …
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E, Zeppieri M, De Maria L, Tedeschi C, Fontanella MM, Panciani PP, Ius T. Agosti E, et al. Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037. Int J Mol Sci. 2023. PMID: 37894718 Free PMC article. Review.
Glioblastoma (GBM) is characterized by aggressive growth and high rates of recurrence. ...
Glioblastoma (GBM) is characterized by aggressive growth and high rates of recurrence. ...
Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.
Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M. Brown TJ, et al. JAMA Oncol. 2016 Nov 1;2(11):1460-1469. doi: 10.1001/jamaoncol.2016.1373. JAMA Oncol. 2016. PMID: 27310651 Free PMC article. Review.
IMPORTANCE: Glioblastoma multiforme (GBM) remains almost invariably fatal despite optimal surgical and medical therapy. ...
IMPORTANCE: Glioblastoma multiforme (GBM) remains almost invariably fatal despite optimal surgical and medical therapy. ...
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C, Lawrie TA, Rogozińska E, Kernohan A, Robinson T, Jefferies S. McBain C, et al. Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2. Cochrane Database Syst Rev. 2021. PMID: 34559423 Free PMC article. Review.
BACKGROUND: Glioblastoma (GBM) is a highly malignant brain tumour that almost inevitably progresses or recurs after first line standard of care. ...OBJECTIVES: To evaluate the effectiveness of further treatment/s for first and subsequent progression or recurrence of gli …
BACKGROUND: Glioblastoma (GBM) is a highly malignant brain tumour that almost inevitably progresses or recurs after first line standa …
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J. Mohile NA, et al. J Clin Oncol. 2022 Feb 1;40(4):403-426. doi: 10.1200/JCO.21.02036. Epub 2021 Dec 13. J Clin Oncol. 2022. PMID: 34898238
People with astrocytoma, IDH-mutant, CNS WHO grade 4 may follow recommendations for either astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 or glioblastoma, IDH-wildtype, CNS WHO grade 4. Concurrent TMZ and RT should be offered to patients with newly diagnosed …
People with astrocytoma, IDH-mutant, CNS WHO grade 4 may follow recommendations for either astrocytoma, IDH-mutant, 1p19q non-codeleted CNS …
Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM. Ballo MT, et al. J Neurooncol. 2023 Aug;164(1):1-9. doi: 10.1007/s11060-023-04348-w. Epub 2023 Jul 26. J Neurooncol. 2023. PMID: 37493865 Free PMC article. Review.
PURPOSE: Tumor Treating Fields (TTFields) therapy, an electric field-based cancer treatment, became FDA-approved for patients with newly diagnosed glioblastoma (GBM) in 2015 based on the randomized controlled EF-14 study. ...
PURPOSE: Tumor Treating Fields (TTFields) therapy, an electric field-based cancer treatment, became FDA-approved for patients with newly dia …
Modifiable risk factors for glioblastoma: a systematic review and meta-analysis.
Yoshikawa MH, Rabelo NN, Telles JPM, Figueiredo EG. Yoshikawa MH, et al. Neurosurg Rev. 2023 Jun 20;46(1):143. doi: 10.1007/s10143-023-02051-y. Neurosurg Rev. 2023. PMID: 37340151 Review.
Glioblastoma (GBM) is the most common and aggressive glioma histological subtype, associated with high disability and poor survival. ...Electronic search was performed by two reviewers independently using the keywords and MeSH terms 'glioblastoma' OR 'glioma' OR 'br …
Glioblastoma (GBM) is the most common and aggressive glioma histological subtype, associated with high disability and poor survival. …
Nivolumab for newly and recurrent glioblastoma multiforme treatment: A systematic review and meta-analysis.
Araujo Moura AW, da Silva Rodrigues S, de Oliveira TF, Lobato BM, Pereira Cerize NN, Léo P. Araujo Moura AW, et al. J Oncol Pharm Pract. 2023 Oct;29(7):1736-1747. doi: 10.1177/10781552231190104. Epub 2023 Jul 28. J Oncol Pharm Pract. 2023. PMID: 37503551 Review.
After conducting a thorough analysis, our meta-analysis indicated that treatment with Nivolumab led to improved overall survival (OS) outcomes in newly diagnosed glioblastoma patients, as evidenced by a prolonged median OS based on trial data. ...CONCLUSIONS: In conclusion …
After conducting a thorough analysis, our meta-analysis indicated that treatment with Nivolumab led to improved overall survival (OS) outcom …
340 results